Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||BNC105P + Ibrutinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|BNC105P||BNC 105P|BNC 105P||BNC105P is a prodrug that upon intracellular conversion to BNC105 selectively inhibits tubulin polymerization, which potentially interferes with tumor vasculature, and may induce tumor cell necrosis and reduce tumor growth (PMID: 20515948).|
|Ibrutinib||Imbruvica||PCI-32765||BTK inhibitor 33 EGFR Inhibitor (Pan) 57 HER2 Inhibitor 39||Imbruvica (ibrutinib) is a selective, irreversible inhibitor of Bruton's tyrosine kinase (BTK), which promotes apoptosis and inhibits B-cell mediated signaling pathways, and has additional activity against ERBB2 (HER2) and EGFR (PMID: 20615965, PMID: 21422473, PMID: 27678331). Imbruvica (Ibrutinib) is FDA approved for use in patients with mantle cell lymphoma, CLL/SLL and CLL/SLL with del 17p, Waldenstroem’s macroglobulinemia, marginal zone lymphoma, and in combination with Rituxan (rituximab) for untreated CLL/SLL (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03454165||Phase I||BNC105P + Ibrutinib||A Study of BNC105P Combined With Ibrutinib||Completed||USA||0|